Oncology Innovations: DATA-Driven Decisions: New Guidelines for Personalized Thyroid Cancer Care

CME/CE
Jointly provided by The Postgraduate Institute for Medicine (PIM) and DKBmed, LLC.  

Acknowledgement
This activity is supported by an independent educational grant from Eisai. 

Target Audience
The intended audience for this Do It Better RealCME program is oncology, endocrinology, and surgical healthcare professionals (MD/DOs, PAs, NPs, RNs, and PharmDs). 

Educational Objectives
Upon completion of this activity, participants should be able to:  

• Apply recent thyroid cancer guideline updates to optimize diagnosis, staging, and treatment selection across for differentiated thyroid cancer (DTC). 

• Evaluate and incorporate emerging and approved therapeutic options into evidence-based, patient-centered management strategies for advanced and radioactive iodine refractory (RAIR) thyroid cancers. 

Faculty and Disclosure of Financial Relationships
PIM requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Faculty / Presenter Reported Financial Relationship 

The PIM planners and others have nothing to disclose. The DKBmed planners and others have nothing to disclose.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine (PIM) and DKBmed LLC. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
PIM designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is .75 contact hours.

PA Continuing Medical Education
 PIM has been authorized by the American Academy of PAs (AAPA) to award AAPA   Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .75 AAPA Category 1 CME credits. Approval is valid until August 13, 2027. PAs should only claim credit commensurate with the extent of their participation.

Pharmacist Continuing Education
PIM designates this continuing education activity for .75 contact hour(s) (.75 CEUs) of the Accreditation Council for Pharmacy Education. 

Universal Activity Numbers: JA4008162-9999-26-543-H01-P 

Type of Activity: Application
For Pharmacists (for live activities): Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted. 

For Pharmacists (for enduring activities): Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

There are no fees for participating and receiving CME/CE credit for this activity.  

Request for Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.  

• Release date: 8/5/2026 

• Expiration date: 8/4/2027 

Estimated time to complete the activity: 45 minutes

Contact Information
For additional information about the accreditation of this activity, please email inquiries@pimed.com

COURSE VIEWING REQUIREMENTS